Fractional Flow Reserve-guided Stenting Versus Medical Therapy in Atherosclerosis Renal Artery Stenosis

NCT06447740 · tracked via the Priya Life Science China tracker

Sponsor

Peking University First Hospital

Phase

Not applicable

Started

2024-06-03

Last updated

2024-08-16

Condition(s) studied

Renal Artery Stenosis AtheroscleroticSecondary Hypertension Renal Arterial

Investigational drug(s) / intervention(s)

Dopamine →Fractional Flow Reserve, RenalRenal artery stenting

Dopamine: A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status

Fractional Flow Reserve, Renal: Renal FFR will be measured based on SOP

Renal artery stenting: Renal artery stenting will be implanted based on the protocol

Study summary

Although randomized trials have demonstrated there is no benefit of renal-artery stenting in addition to medical therapy for patients with atherosclerosis renal artery stenosis, many patients indeed gained benefit in daily practices after stenting, such as reduction in blood pressure and recovery in renal functions. One important gap is that there is no universal standard to determine whether to stent in these patients. Fraction Flow Reserve (FFR) has been studied for many year in chronic coronary heart disease and FFR-guided revascularization strategy is known to be better than both angiography-guided revascularization and medication alone. Based on the primary finding of FAIR-pilot study (NCT05732077), FFR-guided renal artery stenting is practical.

The overall purpose of the FAIR trial is to compare the clinical outcomes and safety of FFR-guided stenting plus optimal medical treatment (OMT) versus OMT alone in patients with renal-vascular hypertensive patients.

With the 'all comers' design, participants met the inclusive/exclusive criteria will be enrolled, and hyperemic FFR induced by dopamine will be measured in all participants. If FFR is ≥0.80, patients will be treated with OMT alone and follow up. If FFR is \<0.80, participants will be randomized to stenting in the renal artery plus OMT or OMT alone on a 1:1 ratio. The blood pressure and anti-hypertensive medications will be compared before and 3 months after the procedure based on ambulatory blood pressure monitoring, all participants will be followed up for 1 year.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * With recorded hypertension, AND the blood pressure is not controlled (daytime mean SBP ≥135 mmHg and/or DBP ≥85 mmHg based on ABPM) on 2 or more classes of anti-hypertensive drugs; * Evidence of renal artery stenosis and undergoing renal artery angiography; * Able to follow the study protocol and provide informed consent; * Renal artery angiography shows at least 1 main artery with stenosis of 50%-90%, AND the diameter is ≥ 4.0mm. Exclusion Criteria: * SBP ≥200mmHg and/or DBP ≥120mmHg at the day or randomization; * Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis; * Pregnancy or unknown pregnancy status in female of childbearing potential; * Participation in any drug or device trial during the study period; * Any stroke/TIA, OR with ≥70% stenosis of carotid artery; * Any major surgery, myocardial infarction or interventional therapy 30 days prior to study entry; * LVEF \<30%; * Comorbidity condition causing life expectancy ≤1 year; * Allergy to contrast or any of the following: aspirin, clopidogrel; * Previous kidney transplant; * Previous renal artery bypass surgery or stent intervention; * Kidney size less than 8 cm measured by ultrasound; * Local lab serum Cr \>3.0 mg/dl (265.2μmol/l) on the day of randomization; * Reference vessel size \<4 mm or \>8 mm.

Primary outcome measure(s)

Change in daytime mean systolic blood pressure as measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM) — From baseline to 3 months post-procedure
Change in the composite index of antihypertensive drugs — From baseline to 3 months post-procedure
Change in the composite index of antihypertensive drugs. Drug Composite Index = Weight (number of classes of antihypertensive drugs) × (sum of doses)

Trial sites (1)

Facility	City	Region	Status
Peking University First Hospital	Beijing	Beijing Municipality	Recruiting

More Peking University First Hospital trials in China

Optimizing Prostate Biopsy Schemes in Men With Multiple MRI Visible Lesions Recruiting

Intranasal Dexmedetomidine-esketamine Administration and Postoperative Pain in Pediatric Patients Recruiting

Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019 Starting soon

Dexmedetomidine-esketamine and tDCS for Prevention of Neurocognitive Complications After Surgery Starting soon

Targeted Temperature Management on Delayed Neurocognitive Recovery in Older Patients After Major Cancer Surgery Starting soon

Other trials for the same condition

A Placebo-controlled Trial of Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Among Atherosclerosis Renal-vascular Hypertension Patients Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06447740 on ClinicalTrials.gov ↗ ← All trials in China